Edition:
India

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.51USD
1:30am IST
Change (% chg)

$0.01 (+0.67%)
Prev Close
$1.50
Open
$1.47
Day's High
$1.54
Day's Low
$1.46
Volume
109,188
Avg. Vol
188,209
52-wk High
$2.55
52-wk Low
$0.75

Chart for

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $299.88
Shares Outstanding(Mil.): 147.00
Dividend: --
Yield (%): --

Financials

BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz

* DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE)

09 May 2018

BRIEF-Durect Corporation Q1 Loss Per Share $0.05

* DURECT CORPORATION ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

03 May 2018

BRIEF-Durect Announces FDA Advisory Committee Meeting For Remoxy Er

* DURECT ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY® ER

20 Mar 2018

BRIEF-Durect Corporation Qtrly Earnings Per Share ‍$0.05​

* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND UPDATE OF PROGRAMS

02 Mar 2018

BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928

* DURECT CORP SAYS COMMENCED PATIENT DOSING IN A PHASE 2A CLINICAL TRIAL OF DUR-928 IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) - SEC FILING

26 Feb 2018

Earnings vs. Estimates